Chapter/Section Purchase

1 Study Coverage
1.1 Overactive Bladder Drug Product Introduction
1.2 Market by Type
1.2.1 Global Overactive Bladder Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Anticholinergics
1.2.3 Solifenacin
1.2.4 Oxybutynin
1.2.5 Darifenacin
1.2.6 Fesoterodine
1.2.7 Tolterodine
1.2.8 Trospium
1.2.9 Others
1.3 Market by Application
1.3.1 Global Overactive Bladder Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Idiopathic Bladder Overactivity
1.3.3 Neurogenic Bladder Overactivity
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Overactive Bladder Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Overactive Bladder Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Overactive Bladder Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Overactive Bladder Drug Sales by Region
2.4.1 Global Overactive Bladder Drug Sales by Region (2017-2022)
2.4.2 Global Sales Overactive Bladder Drug by Region (2023-2028)
2.5 Global Overactive Bladder Drug Revenue by Region
2.5.1 Global Overactive Bladder Drug Revenue by Region (2017-2022)
2.5.2 Global Overactive Bladder Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Overactive Bladder Drug Sales by Manufacturers
3.1.1 Global Top Overactive Bladder Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Overactive Bladder Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Overactive Bladder Drug in 2021
3.2 Global Overactive Bladder Drug Revenue by Manufacturers
3.2.1 Global Overactive Bladder Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Overactive Bladder Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Overactive Bladder Drug Revenue in 2021
3.3 Global Overactive Bladder Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Overactive Bladder Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Overactive Bladder Drug Sales by Type
4.1.1 Global Overactive Bladder Drug Historical Sales by Type (2017-2022)
4.1.2 Global Overactive Bladder Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Overactive Bladder Drug Sales Market Share by Type (2017-2028)
4.2 Global Overactive Bladder Drug Revenue by Type
4.2.1 Global Overactive Bladder Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Overactive Bladder Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Overactive Bladder Drug Revenue Market Share by Type (2017-2028)
4.3 Global Overactive Bladder Drug Price by Type
4.3.1 Global Overactive Bladder Drug Price by Type (2017-2022)
4.3.2 Global Overactive Bladder Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Overactive Bladder Drug Sales by Application
5.1.1 Global Overactive Bladder Drug Historical Sales by Application (2017-2022)
5.1.2 Global Overactive Bladder Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Overactive Bladder Drug Sales Market Share by Application (2017-2028)
5.2 Global Overactive Bladder Drug Revenue by Application
5.2.1 Global Overactive Bladder Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Overactive Bladder Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Overactive Bladder Drug Revenue Market Share by Application (2017-2028)
5.3 Global Overactive Bladder Drug Price by Application
5.3.1 Global Overactive Bladder Drug Price by Application (2017-2022)
5.3.2 Global Overactive Bladder Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Overactive Bladder Drug Market Size by Type
6.1.1 North America Overactive Bladder Drug Sales by Type (2017-2028)
6.1.2 North America Overactive Bladder Drug Revenue by Type (2017-2028)
6.2 North America Overactive Bladder Drug Market Size by Application
6.2.1 North America Overactive Bladder Drug Sales by Application (2017-2028)
6.2.2 North America Overactive Bladder Drug Revenue by Application (2017-2028)
6.3 North America Overactive Bladder Drug Market Size by Country
6.3.1 North America Overactive Bladder Drug Sales by Country (2017-2028)
6.3.2 North America Overactive Bladder Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Overactive Bladder Drug Market Size by Type
7.1.1 Europe Overactive Bladder Drug Sales by Type (2017-2028)
7.1.2 Europe Overactive Bladder Drug Revenue by Type (2017-2028)
7.2 Europe Overactive Bladder Drug Market Size by Application
7.2.1 Europe Overactive Bladder Drug Sales by Application (2017-2028)
7.2.2 Europe Overactive Bladder Drug Revenue by Application (2017-2028)
7.3 Europe Overactive Bladder Drug Market Size by Country
7.3.1 Europe Overactive Bladder Drug Sales by Country (2017-2028)
7.3.2 Europe Overactive Bladder Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Overactive Bladder Drug Market Size by Type
8.1.1 Asia Pacific Overactive Bladder Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Overactive Bladder Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Overactive Bladder Drug Market Size by Application
8.2.1 Asia Pacific Overactive Bladder Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Overactive Bladder Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Overactive Bladder Drug Market Size by Region
8.3.1 Asia Pacific Overactive Bladder Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Overactive Bladder Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Overactive Bladder Drug Market Size by Type
9.1.1 Latin America Overactive Bladder Drug Sales by Type (2017-2028)
9.1.2 Latin America Overactive Bladder Drug Revenue by Type (2017-2028)
9.2 Latin America Overactive Bladder Drug Market Size by Application
9.2.1 Latin America Overactive Bladder Drug Sales by Application (2017-2028)
9.2.2 Latin America Overactive Bladder Drug Revenue by Application (2017-2028)
9.3 Latin America Overactive Bladder Drug Market Size by Country
9.3.1 Latin America Overactive Bladder Drug Sales by Country (2017-2028)
9.3.2 Latin America Overactive Bladder Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Overactive Bladder Drug Market Size by Type
10.1.1 Middle East and Africa Overactive Bladder Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Overactive Bladder Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Overactive Bladder Drug Market Size by Application
10.2.1 Middle East and Africa Overactive Bladder Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Overactive Bladder Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Overactive Bladder Drug Market Size by Country
10.3.1 Middle East and Africa Overactive Bladder Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Overactive Bladder Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Astellas Pharma, Inc. (Japan)
11.1.1 Astellas Pharma, Inc. (Japan) Corporation Information
11.1.2 Astellas Pharma, Inc. (Japan) Overview
11.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Astellas Pharma, Inc. (Japan) Recent Developments
11.2 Pfizer, Inc. (US)
11.2.1 Pfizer, Inc. (US) Corporation Information
11.2.2 Pfizer, Inc. (US) Overview
11.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Pfizer, Inc. (US) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Pfizer, Inc. (US) Recent Developments
11.3 Teva Pharmaceutical Industries Limited (Israel)
11.3.1 Teva Pharmaceutical Industries Limited (Israel) Corporation Information
11.3.2 Teva Pharmaceutical Industries Limited (Israel) Overview
11.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Developments
11.4 Allergan, Plc (Ireland)
11.4.1 Allergan, Plc (Ireland) Corporation Information
11.4.2 Allergan, Plc (Ireland) Overview
11.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Allergan, Plc (Ireland) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Allergan, Plc (Ireland) Recent Developments
11.5 Medtronic plc (Ireland)
11.5.1 Medtronic plc (Ireland) Corporation Information
11.5.2 Medtronic plc (Ireland) Overview
11.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Medtronic plc (Ireland) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Medtronic plc (Ireland) Recent Developments
11.6 Mylan N.V. (US)
11.6.1 Mylan N.V. (US) Corporation Information
11.6.2 Mylan N.V. (US) Overview
11.6.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Mylan N.V. (US) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Mylan N.V. (US) Recent Developments
11.7 Endo International plc (Ireland)
11.7.1 Endo International plc (Ireland) Corporation Information
11.7.2 Endo International plc (Ireland) Overview
11.7.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Endo International plc (Ireland) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Endo International plc (Ireland) Recent Developments
11.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
11.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information
11.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overview
11.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments
11.9 Sanofi (France)
11.9.1 Sanofi (France) Corporation Information
11.9.2 Sanofi (France) Overview
11.9.3 Sanofi (France) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Sanofi (France) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sanofi (France) Recent Developments
11.10 Apotex, Inc. (Canada)
11.10.1 Apotex, Inc. (Canada) Corporation Information
11.10.2 Apotex, Inc. (Canada) Overview
11.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Apotex, Inc. (Canada) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Apotex, Inc. (Canada) Recent Developments
11.11 Cogentix Medical, Inc. (US)
11.11.1 Cogentix Medical, Inc. (US) Corporation Information
11.11.2 Cogentix Medical, Inc. (US) Overview
11.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Cogentix Medical, Inc. (US) Recent Developments
11.12 Aurobindo Pharma Limited (India)
11.12.1 Aurobindo Pharma Limited (India) Corporation Information
11.12.2 Aurobindo Pharma Limited (India) Overview
11.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Aurobindo Pharma Limited (India) Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Overactive Bladder Drug Industry Chain Analysis
12.2 Overactive Bladder Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Overactive Bladder Drug Production Mode & Process
12.4 Overactive Bladder Drug Sales and Marketing
12.4.1 Overactive Bladder Drug Sales Channels
12.4.2 Overactive Bladder Drug Distributors
12.5 Overactive Bladder Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Overactive Bladder Drug Industry Trends
13.2 Overactive Bladder Drug Market Drivers
13.3 Overactive Bladder Drug Market Challenges
13.4 Overactive Bladder Drug Market Restraints
14 Key Findings in The Global Overactive Bladder Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer